What did @taylorreidcoachin actually say?
The creator described a personal technique for administering what appears to be a peptide-based eye drop, explaining they aim for the "teardot area," close the eye, and blink it in. They claimed it "doesn't burn" and produces only a mild sensation, adding that common OTC numbing or cooling eye drops feel worse by comparison.
This is a first-person how-to. No product name was mentioned, no peptide was identified by name, and no dosing information was given. The video is squarely in the "technique and sensation" category, not a pharmacology lecture. That context matters when evaluating what they actually got right or wrong.
The "teardot area" likely refers to the caruncle or the inferior conjunctival fornix, the lower inner pocket of the eye, which is a standard target for topical ophthalmic delivery. That part, at least, is anatomically reasonable.
Does the science back this up?
Ocular drug delivery via the conjunctival sac is well-established, but that's where the clean science ends. The tolerability of any eye drop depends almost entirely on its formulation, pH, osmolarity, and preservative content, not the molecule category.
Research on peptide-based ophthalmic formulations is still quite thin. GHK-Cu has shown up in some cosmetic eye area applications, and BPC-157 has been studied for ocular surface healing in animal models (Hsieh et al., 2022, Pharmaceuticals), but clinical human trials on peptide eye drops for systemic or optimization purposes are essentially nonexistent. The claim that the drops have "a little bit of a slight feeling" but are tolerable is plausible for a well-buffered, preservative-free formulation. Whether compounded peptide eye drops meet that standard is not something any TikTok video can confirm.
The comparison to OTC cooling or numbing drops is subjective and anecdotal. Numbing agents like tetrahydrozoline or naphazoline can cause rebound redness and vasoconstriction with frequent use (Bhatt et al., 2014, Journal of Ocular Pharmacology and Therapeutics), so the creator's implicit critique of those products isn't baseless, even if their reasoning is informal.
What did they get wrong (or right)?
Credit where it's due: the instillation technique described is generally consistent with standard ophthalmic drop administration. Targeting the lower conjunctival pocket, closing the eye, and blinking to distribute is a reasonable approach. Ophthalmologists recommend essentially the same thing.
What's missing is more concerning than what's wrong. The creator never identifies what peptide they're using, who prescribed it, whether it came from a licensed compounding pharmacy, or what concentration it is. Ophthalmic formulations require sterility standards that are stricter than injectable peptides. Contaminated or improperly compounded eye drops have caused serious infections, including cases of endophthalmitis, a sight-threatening condition (CDC outbreak investigations, 2023). That's not a hypothetical risk.
Saying it "doesn't burn" and feels better than OTC drops is an n-of-1 observation. It may be true for their specific product. It tells you nothing about whether peptide eye drops are broadly safe, well-tolerated, or appropriate for anyone else to self-administer.
What should you actually know?
If you're considering any peptide-based ophthalmic product, the formulation quality is the ballgame. Sterility, pH (ideally 6.5 to 7.4 for ocular comfort), osmolarity, and preservative choice all affect both tolerability and safety in ways that visual content cannot assess.
Compounded ophthalmic preparations are subject to USP 797 sterility requirements, but enforcement varies by pharmacy and state. A product that looks clear and doesn't sting is not evidence of safety. The 2023 CDC investigation into contaminated eye drops causing drug-resistant bacterial infections and vision loss should be a standing reminder that source and sterility matter enormously.
The "teardot" technique the creator describes is fine as far as drop placement goes. The problem is the broader context of self-administering an unidentified compounded peptide into your eye based on a TikTok. If you're pursuing peptide-based ophthalmic therapy, it should come through a licensed provider who can verify the formulation, confirm the pharmacy's compliance record, and monitor your ocular health. That's not overcaution. That's just how eyes work.